Tamoxifen tablets 10mg, No. 30

• Breast cancer in postmenopausal women,

• breast cancer in men after castration,

• kidney cancer,

• melanoma (containing estrogen receptors),

• ovarian cancer;

• prostate cancer with resistance to other drugs.

The dosage regimen is set individually, depending on the indications, the patient's condition and the applied anticancer therapy regimen.

Pills

active substance: tamoxifen

• Thrombophlebitis

• pregnancy,

• hypersensitivity to tamoxifen.

pharmachologic effect

Antineoplastic agent.

Antiestrogen. Blocks estrogen receptors and thus inhibits the progression of estrogen-stimulated neoplastic disease. Pharmacokinetics Tamoxifen is metabolized in the liver and undergoes enterohepatic recirculation. It is excreted in the bile in the form of metabolites.

Side effect

From the digestive system: nausea, vomiting, increased activity of hepatic transaminases; in some cases - fatty liver, cholestasis, hepatitis. From the side of the central nervous system: rarely - depression, dizziness, headache, retrobulbar neuritis. From the side of the organ of vision: rarely - retinopathy, keratopathy, cataract. From the hematopoietic system: rarely - thrombocytopenia, leukopenia. From the endocrine system: in women - endometrial hyperplasia, vaginal bleeding, hot flashes, weight gain; in men - impotence, decreased libido. From the side of the cardiovascular system: edema, thromboembolism, phlebitis. Dermatological reactions: alopecia, rash, itching. Others: pain in bones and lesions, fever.

Application during pregnancy and lactation

Tamoxifen is contraindicated in pregnancy. If necessary, use during lactation should stop breastfeeding. In experimental studies, the teratogenic effect of tamoxifen has been established.

special instructions

Use with caution in leukopenia, thrombocytopenia, hypercalcemia, in patients with cataracts, hyperlipidemia. During treatment, you should regularly monitor the peripheral blood picture (especially the number of platelets); blood calcium and glucose levels; with prolonged use, observation by an ophthalmologist is indicated (every 3 months). Should not be combined with preparations containing hormones, especially estrogens. With simultaneous use with drugs that affect the blood coagulation system, a dose adjustment of tamoxifen is necessary. In experimental studies, the carcinogenic effect of tamoxifen has been established.

Drug interactions

With simultaneous use with anticoagulants with coumarin derivatives, the risk of increased anticoagulant action increases; with cytostatics - an increase in the risk of thrombus formation is possible. With simultaneous use with allopurinol, a hepatotoxic effect is possible; with aminoglutethimide - a decrease in the concentration of tamoxifen in plasma, apparently due to an increase in its metabolism. Patients receiving tamoxifen may have prolonged neuromuscular blockade caused by atracurium. With the simultaneous use of bromocriptine, it is possible to enhance the dopaminergic action of bromocriptine. In patients receiving tamoxifen, when using warfarin, there is a risk of developing a threatening clinical situation: prolongation of prothrombin time, hematuria, hematoma is possible.With simultaneous use with mitomycin, the risk of developing hemolytic uremic syndrome increases. A decrease in the concentration of tamoxifen in blood plasma is possible, which, apparently, is due to the induction of the CYP3A4 isoenzyme under the action of rifampicin. Estrogens can reduce the therapeutic effect of tamoxifen.